HITS Inc.

HITS Inc. is a South Korean biotechnology firm specializing in the innovative use of artificial intelligence to develop pharmaceuticals, enhancing drug discovery processes through advanced technology. Founded in 2020 in Seoul, South Korea, HITS Inc. focuses on leveraging AI technologies for pharmaceutical development.

In October 2026, HITS Inc. raised KRW 18. 3 billion in Series B funding led by Premier Partners, with participation from Yuanta Investment, Samsung Securities, BSK Investment, TBT Partners, IBK Venture Investment, Korea Investment Partners, Capstone Partners, and Laplace Partners. HITS Inc.

specializes in the innovative development of pharmaceuticals through advanced artificial intelligence technologies. It offers a deep learning-integrated virtual exploration system that accelerates the identification of effective compounds, supported by a proprietary virtual library that protects intellectual property. The company employs a molecular pharmacology-inspired design patent technique to optimize new molecular structures across various modalities, including small molecules and peptidomimetics. HITS Inc.

serves clients in the pharmaceutical and biotech industries globally, particularly in North America, Europe, and Asia. HITS Inc. generates revenue through B2B partnerships and direct collaborations with pharmaceutical companies and research institutions. Revenue streams include licensing agreements for HITS Inc.

's proprietary technologies and access to its virtual library and predictive models for drug development, utilizing subscription-based or project-based pricing structures tailored to the complexity of the services offered. HITS Inc. plans to use the October 2026 funding to advance its artificial intelligence technology, expand globally, and develop its artificial intelligence scientist platform.